The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability
- PMID: 30320917
- DOI: 10.1002/jcb.27863
The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability
Erratum in
-
Correction to "The Oncolytic Virus H101 Combined with Gnaq Sirna-Mediated Knockdown Reduces Uveal Melanoma Cell Viability".J Cell Biochem. 2024 Oct;125(10):e30648. doi: 10.1002/jcb.30648. Epub 2024 Sep 6. J Cell Biochem. 2024. PMID: 39238337 No abstract available.
Abstract
Background: Uveal melanoma (UM) is a severe human malignancy with a high mortality rate, as well as high metastasis and recurrence potential. The active mutation of G protein subunit alpha q (GNAQ) or G protein subunit alpha 11 (GNA11) is a major trigger for UM. Oncolytic adenovirus H101 (H101) is the first oncolytic virus approved for clinical applications in cancer therapy by the China Food and Drug Administration. We investigated whether combining H101 with the downregulation of GNAQ expression would act synergistically in UM therapy.
Methods: Three UM cell lines OMM2.3 and 92.1, harboring GNAQ mutation, and OCM1, harboring B-Raf proto-oncogene mutation, were chosen for our research. The cellular toxicity of adenoviral infection and the cell growth rate were measured with a Cell Counting Kit-8. Western blot analysis was used to detect GNAQ, p-MEK1/2, YAP, and p-YAP expression. The apoptosis and cell-cycle distribution of cells were evaluated with annexin-V and propidium iodide staining.
Results: Our results revealed that OMM2.3 and 92.1 cells were more sensitive to H101 infection than OCM1 cells. GNAQ expression was markedly reduced by small interfering RNA, siGNAQ. Combined treatment of siGNAQ and H101 inhibited the proliferation and activated the apoptosis of OMM2.3 and 92.1 cells by blocking the phosphorylation of MEK1/2 and increasing the phosphorylation of YAP.
Conclusions: In summary, a therapy combining H101 and siGNAQ is feasible, with potential utility as a novel targeted molecular therapy for UM, especially those carrying a GNAQ mutation.
Keywords: G protein subunit alpha q (GNAQ); H101; Yes-associated protein (YAP) pathway; melanoma; uveal melanoma.
© 2018 Wiley Periodicals, Inc.
Similar articles
-
Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.Br J Ophthalmol. 2012 Oct;96(10):1331-8. doi: 10.1136/bjophthalmol-2011-301470. Epub 2012 Jul 27. Br J Ophthalmol. 2012. PMID: 22843987
-
Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.Invest Ophthalmol Vis Sci. 2014 Apr 7;55(4):2130-9. doi: 10.1167/iovs.13-13468. Invest Ophthalmol Vis Sci. 2014. PMID: 24595385 Free PMC article.
-
Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.Oncol Rep. 2015 Jul;34(1):295-301. doi: 10.3892/or.2015.3949. Epub 2015 May 5. Oncol Rep. 2015. PMID: 25955651
-
[Uveal Melanoma: Molecular and Genetic Mechanisms of Development and Therapeutic Approaches].Mol Biol (Mosk). 2024 Mar-Apr;58(2):189-203. Mol Biol (Mosk). 2024. PMID: 39355878 Review. Russian.
-
What hope for the future? GNAQ and uveal melanoma.Br J Ophthalmol. 2011 May;95(5):620-3. doi: 10.1136/bjo.2010.182097. Epub 2011 Mar 3. Br J Ophthalmol. 2011. PMID: 21378004 Review.
Cited by
-
Quercetin Mediated TET1 Expression Through MicroRNA-17 Induced Cell Apoptosis in Melanoma Cells.Biochem Genet. 2023 Apr;61(2):762-777. doi: 10.1007/s10528-022-10286-5. Epub 2022 Sep 22. Biochem Genet. 2023. PMID: 36136257
-
Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts.Cancer Manag Res. 2020 Nov 18;12:11803-11812. doi: 10.2147/CMAR.S274605. eCollection 2020. Cancer Manag Res. 2020. PMID: 33239914 Free PMC article.
-
Biological characteristics and clinical management of uveal and conjunctival melanoma.Oncol Res. 2024 Jul 17;32(8):1265-1285. doi: 10.32604/or.2024.048437. eCollection 2024. Oncol Res. 2024. PMID: 39055896 Free PMC article. Review.
-
Recent Advances and Challenges in Uveal Melanoma Immunotherapy.Cancers (Basel). 2022 Jun 23;14(13):3094. doi: 10.3390/cancers14133094. Cancers (Basel). 2022. PMID: 35804863 Free PMC article. Review.
-
Enhancing the immune effect of oHSV-1 therapy through TLR3 signaling in uveal melanoma.J Cancer Res Clin Oncol. 2023 Feb;149(2):901-912. doi: 10.1007/s00432-022-04272-y. Epub 2022 Aug 28. J Cancer Res Clin Oncol. 2023. PMID: 36030435
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous